Methylated tirilazad alleviates colitis not merely through direct anti-inflammatory action, but via a reciprocal microbiome-metabolome reprogramming loop, wherein microbial restructuring drives metabolome correction, which in turn reinforces barrier integrity and immune homeostasis.
Methylated tirilazad (MT) ameliorated clinical severity of DSS-induced colitis in C57BL/6 mice.
MT reversed DSS-induced gut dysbiosis, specifically enriching the probiotic species Lactobacillus johnsonii while suppressing pathobionts.
MT normalized colitis-associated metabolic disturbances, downregulating the pro-inflammatory eicosanoid 12R-HETE and upregulating barrier-supportive dipeptides.
Integrated correlation network analysis identified 12R-HETE as a key node linking pathogenic bacteria, inflammation, and barrier dysfunction.
MT directly inhibited LPS-induced pro-inflammatory cytokine expression in human intestinal Caco-2 cells in vitro.
MT is a synthetic 21-aminosteroid with antioxidant properties derived from tirilazad, hypothesized to alleviate colitis through microbiome and metabolic reprogramming.
This research suggests that a modified compound called methylated tirilazad (MT) can effectively reduce colitis symptoms in mice, and that it does so through a more comprehensive mechanism than simply suppressing inflammation. In experiments using a standard mouse model of ulcerative colitis (UC), MT reduced levels of inflammatory proteins, restored the protective lining of the gut, and decreased oxidative damage. Critically, MT also dramatically changed the composition of gut bacteria — increasing beneficial bacteria like Lactobacillus johnsonii by more than 8-fold and reducing harmful bacteria like Desulfovibrio fairfieldensis by more than 13-fold. The study also found that MT corrected the disrupted chemical environment of the gut, lowering a pro-inflammatory signaling molecule called 12R-HETE and increasing protective compounds called dipeptides. Through sophisticated data analysis combining the microbiome and metabolite findings, 12R-HETE emerged as a central hub connecting harmful bacteria, inflammation, and gut barrier breakdown. Additional lab experiments using human intestinal cells confirmed that MT can directly suppress inflammatory responses, independent of any effects on gut bacteria. This research suggests that MT may address both the symptoms and underlying causes of UC by simultaneously targeting gut bacteria, their metabolic products, gut barrier integrity, and inflammatory pathways in a coordinated way. This positions MT as a potentially novel therapeutic candidate that goes beyond current UC treatments, which typically focus only on reducing inflammation without correcting the disrupted gut bacterial ecosystem. Further research in humans would be needed to determine if these findings translate to clinical use.
Tuniyazi M, Gao R, Song H, Zhao L, Reheman A, Qi M. (2026). Methylated tirilazad alleviates DSS-induced colitis in mice through reciprocal microbiome-metabolome.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. https://doi.org/10.1016/j.biopha.2026.119468